Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database - Top-Institutions - MDSpire

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database

  • By

  • Ruming Liu

  • Yaoyu Xiang

  • Xidan Hu

  • Min Zhang

  • Lujie Wang

  • Tao Liu

  • Xi Wang

  • Bin Qian

  • June 18, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School
    Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School

    Newark, New Jersey

    Key Differentiators

    • Oncology

  • #4

    Sunnybrook Health Sciences Centre
    Sunnybrook Health Sciences Centre

    Toronto, Ontario

    Key Differentiators

    • Oncology

Original Source(s)

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database

  • by Ruming Liu, Yaoyu Xiang, Xidan Hu, Min Zhang, Lujie Wang, Tao Liu, Xi Wang, Bin Qian

  • June 18, 2026

Related Content

Case Report: Malignant transformation of deep infiltrating endometriosis: a report of two cases and literature review

Malignant transformation of uterine serosal endometriosis to clear cell carcinoma in a postmenopausal patient: a rare case report

Polygenic Risk Scores for Breast Cancer Among African American Women With High Risk